Lin Guey

Dr. Guey is a leading expert in mRNA therapeutics and Moderna’s CSO of External Research Ventures. In this role, she oversees Moderna’s partnership with Carisma to develop in vivo CAR-M therapies. Dr. Guey brings nearly 15 years of drug development experience in program leadership, research, and nonclinical development. Prior to joining Moderna, Dr. Guey served in senior leadership roles for Tessera, Xilio, Shire, and Pfizer.

Dr. Guey received her PhD in statistics and BS in mathematics from Stony Brook University, and completed her postdoctoral research fellowship in genetic and molecular epidemiology at the Spanish National Cancer Research Centre.